Xbrane Biopharma Q2 2025: Important months ahead - Redeye

Redeye updates its view on Xbrane following its Q2 report. The BsUFA date at the end of October), which could open the US market for its ranibizumab biosimilar, marks an important potential catalyst for the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1123114/xbrane-biopharma-q2-2025-important-months-ahead?utm_source=finwire&utm_medium=RSS